At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LUCD LUCID DIAGNOSTICS INC.
Trading 11-22 15:01:25 EST
0.9917
-0.0073
-0.73%
High1.02
Low0.9600
Vol577.78K
Open0.9800
D1 Closing0.9990
Amplitude6.01%
Mkt Cap58.85M
Tradable Cap24.08M
Total Shares59.34M
T/O575.17K
T/O Rate2.38%
Tradable Shares24.28M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Lucid Diagnostics submits clinical evidence for EsoGuard Esophagea DNA test
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.